P08.17 Mitotic checkpoint inhibition augments Tumor-Treating-Field (TTField) effects on glioblastoma cells

av Kessler, A. F.
I publikationen Neuro Oncol (2017)

P09.21 Complete radiological response after subtotal resection in two Gglioblastoma patients treated with Tumor Treating Fields

av Kessler, A. F., Linsenmann, T.
I publikationen Neuro Oncol (2017)

P14.59 Post-Market Surveillance Data of the EMEA region indicate good tolerability of TTFields in WHO Grade III Glioma

av Keßler, A F, Ritz, R
I publikationen Neuro Oncol (2019)

P06.06 Is activating transcription factor 5 (ATF5) a new therapeutic target in astrocytomas of different WHO grades and varying biological behavior? An expression analysis

av Feldheim, J. A., Keßler, A. F.
I publikationen Neuro Oncol (2016)

P08.20 Augmentation of Tumor-Treating-Field (TTField) effects on glioblastoma cells by mitotic checkpoint inhibition

av Frömbling, G. E., Kessler, A. F.
I publikationen Neuro Oncol (2016)

P14.60 FET PET response upon radiochemotherapy followed by Tumor Treating Fields (TTFields) in a patient with progressive high-grade glioma

av Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
I publikationen Neuro Oncol (2019)

P14.28 First report on the combination of axitinib and Tumor Treating Fields (TTFields) in three patients with recurrent glioblastoma

av Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
I publikationen Neuro Oncol (2019)

O4.06 ANALYSIS OF RAF PROTEINS IN MALIGNANT GLIOMAS

av Hagemann, C., Gloger, J., Kessler, A.F., Linsenmann, T., Vince, G.H., Ernestus, R., Löhr, M.
Publicerad 2014

P04.33 Effects of Tumor Treating Fields (TTFields) on blood brain barrier (BBB) permeability

av Kessler, A F, Schaeffer, C, Burek, M, Ruschig, U, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
I publikationen Neuro Oncol (2018)

P01.13 EXPRESSION OF HUMAN ENDOGENOUS RETROVIRUS K (HERV-K) IN HUMAN ASTROCYTIC TUMORS

av Kessler, A.F., Wiesner, M., Denner, J., Kämmerer, U., Löhr, M., Linsenmann, T., Vince, G.H., Ernestus, R., Hagemann, C.
Publicerad 2014

OS4.3 The BReMen trial: Patients with benign meningioma - is rehabilitation really necessary?

av Kessler, A F, Krause, K, Al-Shameri, B, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M, Jentschke, E
I publikationen Neuro Oncol (2018)

P11.28 Alteration of blood brain barrier (BBB) permeability by Tumor Treating Fields (TTFields) in vivo

av Keßler, A F, Salvador, E, Domröse, D, Burek, M, Tempel Brami, C, Voloshin Sela, T, Giladi, M, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
I publikationen Neuro Oncol (2019)

P01.050 Circulating MACC1 transcript plasma levels in glioblastoma patients segregate together with prognostic markers and treatment response

av Hagemann, C, Neuhaus, N, Dahlmann, M, Kessler, A F, Kobelt, D, Herrmann, P, Eyrich, M, Freitag, B, Freitag, B, Linsenmann, T, Monoranu, C M, Ernestus, R, Löhr, M, Stein, U
I publikationen Neuro Oncol (2018)